HORMAD2 and thyroid gland carcinoma: D‘Agostino et al clearly indicated that TSHR and NIS transcript levels in FTC‐133 cells are subjected to different forms of epigenetic control.19 We focused on detecting the methylation level of HORMAD2 and its impact on different subtype thyroid carcinoma (THCA) cells (TPC‐1 and FTC‐133) development.